Antihypertensive drugs: An overview

American Journal of Cardiovascular Drugs

Volumn 2, Issue 2, 2002, Pages 77-89

  Ram, C Venkata S ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; METOLAZONE; MINOXIDIL; POLYTHIAZIDE; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE REGULATION; DEPRESSION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; INSOMNIA; INSULIN RESISTANCE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; NEUTROPENIA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT MONITORING; PHYSICIAN; POLYURIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; XEROSTOMIA;

EID: 0036262916     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202020-00002     Document Type: Article

References (58)

1. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI)
2. Inadequate management of blood pressure in a hypertensive population
3. Diuretics
4. Pharmacology of diuretics
5. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults
6. Moderate sodium restriction and various diuretics in the treatment of hypertension: Effects on potassium wastage and blood pressure control
7. Diuretic complications
8. Does diuretic therapy increase the risk of renal cell carcinoma?
9. β-blockade after myocardial infarction
10. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
11. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina
12. The impact of ethnicity on response to antihypertensive therapy
13. The effects of antihypertensive agents on serum lipids and lipoproteins
14. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone
15. Alpha-adrenergic blockade by Prazosin in therapy of essential hypertension
16. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment
17. Implications of discontinuation of doxazosin arm of ALLHAT
18. Intravenous labetalol in acute aortic dissection
19. Labetalol hepatotoxicity
20. Transdermal clonidine
21. Withdrawal syndrome following cessation of guanabenz therapy
22. Abrupt discontinuation of clonidine therapy
23. On the use of rauwolfia serpentina in high blood pressure
24. Angiotensin-converting enzyme inhibitors
25. Captopril
26. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
27. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks
28. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension
29. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects
30. Hypoglycemia associated with use of inhibitors angiotensin converting enzyme
31. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine
32. Angiotensin II receptor antagonists
33. Angiotensin II antagonists for hypertension: Are there differences in efficacy?
34. Angiotensin II receptors and angiotensin II receptor antagonists
35. Efficacy and tolerability of losartan in hypertensive patients with renal impairment
36. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
37. The role of calcium channel blockers in the treatment of essential hypertension
38. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
39. History and prospects in calcium antagonist research
40. The classification of calcium antagonists and their selection in the treatment of hypertension
41. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine
42. Amlodipine
43. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension
44. Risks of untreated and treated isolated systolic hypertension in the elderly
45. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
46. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage
47. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?
48. The risk of myocardial infarction associated with antihypertensive drug therapies
49. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients
50. Grapefruit-felodipine interaction
51. Seville orange juice-felodipine interaction
52. Direct and reflex cardiostimulating effects of hydralazine
53. Direct vasodilators
54. The lupus syndrome induced by hydralazine
55. Minoxidil: A review of its pharmacological properties and therapeutic use
56. Refractory hypertension
57. Hypertension
58. Pericardial effusion associated with minoxidil therapy